Guide

What a warning letter to a clinical investigator means for a sponsor

An FDA warning letter to a clinical investigator is the agency’s formal, written notice that an inspection found significant violations of the regulations governing clinical research, together with a request for a written response. It is the document most sponsors already check for. It is also the last rung of a ladder, and the rungs below it are where most of the record lives.

What a warning letter is

A warning letter is advisory: it communicates FDA’s position that violations occurred and that prompt correction is expected, and it asks for a response — normally within 15 working days — describing the corrective actions taken and planned. It does not itself impose a penalty, and it does not commit FDA to further action. For a clinical investigator it often follows an inspection classified Official Action Indicated, the most serious inspection classification FDA assigns, after the center has reviewed the inspection report, the Form FDA 483 and any response the investigator sent.

What it cites

A warning letter to a clinical investigator quotes the specific regulations and describes the specific failures. The findings that recur most often, with the regulation behind each:

Obtaining informed consent (21 CFR 312.60) — consent not obtained from each subject, or not in accordance with 21 CFR part 50, before study-related procedures.

Conducting the study (21 CFR 312.60) — the investigation was not conducted according to the signed statement of investigator and the investigational plan.

Case histories (21 CFR 312.62(b)) — failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Control of the investigational drug (21 CFR 312.61) — study drug administered to persons not under the investigator’s personal supervision or that of a subinvestigator responsible to the investigator.

Warning letters also cite supervision failures, unreported deviations, and IRB reporting. Each finding is followed by FDA’s account of what was observed — the subjects, dates and documents involved — which is why the full text of a warning letter is a more useful record than the fact of one.

Why the sponsor usually is not copied

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. A warning letter is addressed to the investigator; the sponsor is not a party to it. The investigator is not required to report it to the sponsor either, unless a quality agreement between them says so — and then possibly only for that sponsor’s trial. Because a large site often runs several trials at once, the inspection behind a warning letter may have concerned another sponsor’s study entirely. None of this is unusual or improper; it is simply how the system is built, and it is why the check is the sponsor’s to run.

Why it matters to the sponsor anyway

Sponsors remain ultimately responsible for the quality and integrity of trial data. If a clinical investigator’s data are questioned, the application that relies on them is questioned; FDA may decline to rely on some or all of a site’s data, and findings at a site can lead to scrutiny of the sponsor’s own monitoring at the sponsor’s inspection. A warning letter on a candidate site’s record is therefore a fact about the sponsor’s risk, not just the investigator’s.

What a sponsor does about one

Where a candidate clinical investigator’s record shows a warning letter — or inspection findings that never reached one — the sponsor has three options, in this order:

1. Ask the site for their responses and corrective action plans. A serious finding that was answered thoroughly and closed out is a different fact from one that was not. The response is the site’s to share.

2. Visit the site before signing. A site qualification visit scoped to the findings: are the corrections in place, and did they hold?

3. Choose a site without this history. A legitimate decision when the protocol’s risks and the findings overlap, and one that is easy to defend when it is written down.

Whichever option is taken, the file should record the warning letter, the date it was reviewed, and the decision. That is the point of the check.

The check most sponsors run, and what it misses

“We checked FDA’s website. No warning letter. That’s usually what we check.” It is a reasonable check, and it should be run. But there is a lot more to inspection history than a warning letter. FDA classifies every inspection it closes; a warning letter follows only some OAI inspections, and a VAI inspection generally does not lead to one, however serious its findings read. Older warning letters are also not always still available, so a clean search can mean “none” or “none still shown”. Reading the inspection history, classifications and findings — clinical investigator vetting — is the fuller check, and the warning letter is one line in it.

Questions this page answers

What is an FDA warning letter to a clinical investigator?

It is FDA’s formal written notice to a clinical investigator that an inspection found significant violations of the regulations governing clinical research, with a request for a written response, normally within 15 working days, describing corrective actions. It often follows an inspection classified Official Action Indicated.

Does FDA send the sponsor a copy of a warning letter to its clinical investigator?

Not typically. FDA sends inspection findings to the clinical investigator, not to the sponsor, and the warning letter is addressed to the investigator. The investigator is not required to tell the sponsor unless a quality agreement says so.

Is a warning letter the same as an OAI?

No. OAI (Official Action Indicated) is the inspection classification; a warning letter is one of the actions that can follow it. Many OAI inspections do not result in a warning letter, and a warning letter is issued where FDA’s review indicates that serious violations occurred.

Can a clinical investigator with a warning letter still run trials?

Yes, unless FDA has also disqualified them. A warning letter is advisory. Whether to select such a clinical investigator is the sponsor’s decision; the usual course is to ask for the site’s responses and corrective action plans, visit before signing, or choose a site without this history.

What is the difference between a Form FDA 483 and a warning letter?

A Form FDA 483 is the list of observations the inspector hands over at the close of the inspection; it is not a final determination. A warning letter can come later, from the center, if FDA’s review indicates that serious violations have occurred. Most 483s never become warning letters.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.